Company
Headquarters: Brisbane, QLD, Australia
Employees: 500
CEO: Dr. Anthony Keating
A$176.2 Million
AUD as of Sept. 1, 2022
US$120.1 Million
Company | Market Cap (USD) |
---|---|
GE HealthCare | $34.86 B |
Veeva Systems Inc. | $29.97 B |
M3, Inc. | $11.24 B |
Change Healthcare Inc. | $9.03 B |
Signify Health, Inc. | $8.38 B |
Company | Market Cap (USD) |
---|---|
Lilly | $586.39 B |
UnitedHealth Group | $504.47 B |
Novo Nordisk | $461.52 B |
Johnson & Johnson | $387.50 B |
Merck | $296.51 B |
ResApp Health Limited develops digital healthcare solutions to assist doctors and allow patients to diagnose and manage respiratory disease. The company offers ResAppDx, a smartphone-based acute respiratory disease diagnostic test for use in telehealth, emergency department, and primary care markets; and SleepCheck, a smartphone application that allows consumers to self-assess the risk of sleep apnoea. Its technology uses sound to diagnose respiratory diseases, including pneumonia, bronchiolitis, bronchitis, chronic obstructive pulmonary disease, and asthma. ResApp Health Limited has a joint development and pilot agreement with Medgate AG to integrate and test smartphone-based acute respiratory diagnostic test. The company was formerly known as Narhex Life Sciences Limited. ResApp Health Limited was incorporated in 2000 and is headquartered in Brisbane, Australia.
Top 1-year algo backtest: +284.14%
$10,000 in April 2023 would now be $38,414 by following this algorithm daily at market close.
Boost your stocks returns with Disfold AI... Now!
Try Disfold AI for FREE
ResApp Health Limited has the following listings and related stock indices.
Stock: ASX: RAP wb_incandescent